Table 2.
9α,11β-PGF2 and PGD2 concentration in pg/ml (Me [min; max]) in the fluid from allergen-challenged chambers and allergen-free chambers in BV-allergic patients and control
| Time/solution/release ratio | Control group | BV group | Control vs BV |
|---|---|---|---|
| 9α,11β-PGF2 (pg/ml) | |||
| 5-min incubation | |||
| BV solution | 10.1 [2.8; 45.5] | 4.9 [1; 1962.6] | p = 0.46 |
| Control solution | 6.3 [1.8; 30.8] | 2.85 [0.9; 22.1] | p = 0.04 |
| Release ratio (BV/control solution) | 1.24 [0.44; 7.88] | 2.15 [0.52; 222.17] | p = 0.26 |
| 15-min incubation | |||
| BV solution | 12.45 [3; 59] | 27.3 [2; 711.8] | p = 0.3 |
| Control solution | 14.2 [3.2; 64.7] | 6.8 [1.5; 48.9] | p = 0.08 |
| Release ratio (BV/control solution) | 0.8 [0.2; 164] | 1.8 [0.5; 385] | p = 0.039 |
| PGD2 (pg/ml) | |||
| 5-min incubation | |||
| BV solution | 181.4 [106; 536.8] | 184.3 [18.2; 9710.6] | p = 0.71 |
| Control solution | 115.2 [35.7; 699.7] | 122.3 [24.5; 490.3] | p = 0.95 |
| Release ratio (BV/control solution) | 2.56 [0.18; 5.36] | 1.48 [0.19; 21.19] | p = 0.79 |
| 15-min incubation | |||
| BV solution | 140.2 [22.8; 299.4] | 314.3 [17.5; 3855.3] | p = 0.23 |
| Control solution | 142.85 [51.7; 315] | 169.7 [24.8;746.2] | p = 0.4 |
| Release ratio (BV/control solution) | 1.17 [0.11; 2.04] | 1.31 [0.09;27.47] | p = 0.54 |
Release ratio ratio of the mediator levels in the fluid chamber after BV incubation solution to the control solution for given patient and time incubation